Literature DB >> 18708053

Gliopathy ensures persistent inflammation and chronic pain after spinal cord injury.

Claire E Hulsebosch1.   

Abstract

Research focused on improving recovery of function, including the reduction of central neuropathic pain (CNP) after spinal cord injury (SCI) is essential. After SCI, regional neuropathic pain syndromes above, at and below the level or spinal injury develop and are thought to have different mechanisms, but may share common dysfunctional glial mechanisms. Detloff et al., [Detloff, M.R., Fisher, L.C., McGaughy, V., Longbrake, E.E., Popovich, P.G., Basso, D.M., Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Exp. Neurol. (2008), doi: 10.1016/j.expneurol.2008.04.009.] describe events in the lumbar region of the spinal cord after a midthoracic SCI injury, the so called "below-level" pain and compares the findings to peripheral nerve lesion findings. This commentary briefly reviews glial contributions and intracellular signaling mechanisms, both neuronal and glial, that provide the substrate for CNP after SCI, including the persistent glial production of factors that can maintain sensitization of dorsal horn neurons in segments remote from the spinal injury; ie. dorsal horn hyperexcitability to formerly non noxious stimuli that become noxious after SCI resulting in allodynia. The term "gliopathy" is proposed to describe the dysfunctional and maladaptive response of glial cells, specifically astrocytes and microglia, to neural injury that is initiated by the sudden injury induced increase in extracellular concentrations of glutamate and concomitant production of several proinflammatory molecules. It is important to understand the roles that different glia play in "gliopathy", a condition that appears to persist after SCI. Furthermore, targeted treatment of gliopathy will attenuate mechanical allodynia in both central and peripheral neuropathic pain syndromes.

Entities:  

Mesh:

Year:  2008        PMID: 18708053      PMCID: PMC2888707          DOI: 10.1016/j.expneurol.2008.07.016

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  49 in total

1.  DNA microarray analysis of the contused spinal cord: effect of NMDA receptor inhibition.

Authors:  O Nesic; N M Svrakic; G-Y Xu; D McAdoo; K N Westlund; C E Hulsebosch; Zeiming Ye; A Galante; P Soteropoulos; P Tolias; W Young; R P Hart; J R Perez-Polo
Journal:  J Neurosci Res       Date:  2002-05-15       Impact factor: 4.164

Review 2.  The role of neuroinflammation and neuroimmune activation in persistent pain.

Authors:  J A DeLeo; R P Yezierski
Journal:  Pain       Date:  2001-02-01       Impact factor: 6.961

3.  Sensory function in spinal cord injury patients with and without central pain.

Authors:  N B Finnerup; I L Johannesen; A Fuglsang-Frederiksen; F W Bach; T S Jensen
Journal:  Brain       Date:  2003-01       Impact factor: 13.501

4.  Strain and model differences in behavioral outcomes after spinal cord injury in rat.

Authors:  C D Mills; B C Hains; K M Johnson; C E Hulsebosch
Journal:  J Neurotrauma       Date:  2001-08       Impact factor: 5.269

5.  Tumor necrosis factor-alpha induces cFOS and strongly potentiates glutamate-mediated cell death in the rat spinal cord.

Authors:  G E Hermann; R C Rogers; J C Bresnahan; M S Beattie
Journal:  Neurobiol Dis       Date:  2001-08       Impact factor: 5.996

6.  Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury.

Authors:  A D Bennett; A W Everhart; C E Hulsebosch
Journal:  Brain Res       Date:  2000-03-17       Impact factor: 3.252

7.  Group I metabotropic glutamate receptors in spinal cord injury: roles in neuroprotection and the development of chronic central pain.

Authors:  Charles D Mills; Kathia M Johnson; Claire E Hulsebosch
Journal:  J Neurotrauma       Date:  2002-01       Impact factor: 5.269

8.  Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats.

Authors:  Erin D Milligan; Carin Twining; Marucia Chacur; Joseph Biedenkapp; Kevin O'Connor; Stephen Poole; Kevin Tracey; David Martin; Steven F Maier; Linda R Watkins
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 9.  Cell death in models of spinal cord injury.

Authors:  Michael S Beattie; Gerlinda E Hermann; Richard C Rogers; Jacqueline C Bresnahan
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

10.  Nuclear factor-kappaB decoy amelioration of spinal cord injury-induced inflammation and behavior outcomes.

Authors:  Danny Salah Rafati; Katja Geissler; Kathia Johnson; Geda Unabia; Claire Hulsebosch; Olivera Nesic-Taylor; J Regino Perez-Polo
Journal:  J Neurosci Res       Date:  2008-02-15       Impact factor: 4.164

View more
  52 in total

1.  Role of microglia and astrocyte in central pain syndrome following electrolytic lesion at the spinothalamic tract in rats.

Authors:  Kobra Naseri; Elham Saghaei; Fatemeh Abbaszadeh; Mina Afhami; Ali Haeri; Farzaneh Rahimi; Masoumeh Jorjani
Journal:  J Mol Neurosci       Date:  2012-06-22       Impact factor: 3.444

2.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila Keresztes; Jiyang Ren; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  J Neuroimmunol       Date:  2012-01-30       Impact factor: 3.478

3.  Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury.

Authors:  Darryl Lau; Steven E Harte; Thomas J Morrow; Shiyong Wang; Marina Mata; David J Fink
Journal:  Neurorehabil Neural Repair       Date:  2012-05-15       Impact factor: 3.919

4.  Upregulation of inflammatory mediators in a model of chronic pain after spinal cord injury.

Authors:  Rajat Sandhir; Eugene Gregory; Yong-Yue He; Nancy E J Berman
Journal:  Neurochem Res       Date:  2011-02-03       Impact factor: 3.996

5.  Inhibition of NOX2 signaling limits pain-related behavior and improves motor function in male mice after spinal cord injury: Participation of IL-10/miR-155 pathways.

Authors:  Boris Sabirzhanov; Yun Li; Marino Coll-Miro; Jessica J Matyas; Junyun He; Alok Kumar; Nicole Ward; Jingwen Yu; Alan I Faden; Junfang Wu
Journal:  Brain Behav Immun       Date:  2019-02-23       Impact factor: 7.217

Review 6.  Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury.

Authors:  Alan I Faden; Junfang Wu; Bogdan A Stoica; David J Loane
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

7.  Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A.

Authors:  Dou Yu; Devang K Thakor; Inbo Han; Alexander E Ropper; Hariprakash Haragopal; Richard L Sidman; Ross Zafonte; Steven C Schachter; Yang D Teng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-05       Impact factor: 11.205

8.  Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage.

Authors:  Jonghyuck Park; Lingxing Zheng; Andrew Marquis; Michael Walls; Brad Duerstock; Amber Pond; Sasha Vega-Alvarez; He Wang; Zheng Ouyang; Riyi Shi
Journal:  J Neurochem       Date:  2013-12-15       Impact factor: 5.372

9.  Transplantation of glial progenitors that overexpress glutamate transporter GLT1 preserves diaphragm function following cervical SCI.

Authors:  Ke Li; Elham Javed; Tamara J Hala; Daniel Sannie; Kathleen A Regan; Nicholas J Maragakis; Megan C Wright; David J Poulsen; Angelo C Lepore
Journal:  Mol Ther       Date:  2014-12-10       Impact factor: 11.454

10.  Metabolomics uncovers dietary omega-3 fatty acid-derived metabolites implicated in anti-nociceptive responses after experimental spinal cord injury.

Authors:  J D Figueroa; K Cordero; M Serrano-Illan; A Almeyda; K Baldeosingh; F G Almaguel; M De Leon
Journal:  Neuroscience       Date:  2013-09-14       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.